Medicine. Stroke--tPA and the clinic.
Clinical trial results are not always rapidly incorporated into routine medical practice. This Policy Forum describes a variety of barriers that have impeded the more widespread use of thrombolytic therapy (tPA, tissue plasminogen activator) for selected patients with acute ischemic stroke. These barriers are not insurmountable but will require a concerted effort to overcome.
D000818:Animals; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy*; D003695:Delivery of Health Care; D004363:Drug Utilization; D004632:Emergency Medical Services; D004634:Emergency Medical Technicians; D004636:Emergency Service, Hospital; D006266:Health Education; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012017:Referral and Consultation; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator